Chief Scientific Officer
David Gauden is the Chief Scientific Officer at Blue Earth Diagnostics. Prior to joining Blue Earth he was Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the portfolio mix, licensing, product development and strategic marketing activities for a range of developmental PET drugs. Now with more than 20 years in the medical imaging industry, David has deep expertise across the business spectrum. He held roles of increasing seniority within supply chain, project management, IP licensing and clinical development. David has an undergraduate degree from the University of Warwick and a doctorate in Biochemistry from the University of Oxford.
Director of Regulatory Affairs
Helen Barker is Director of Regulatory Affairs at Blue Earth Diagnostics. Helen has over twenty years’ experience in the management of regulatory affairs for the global pharmaceutical industry. She has deep sector expertise, having worked at levels of increasing seniority with a number of leading pharmaceutical companies including GSK, Janssen and Abbvie. Helen graduated from the University of Warwick with a degree in Microbiology and Microbial Technology, and has a PhD from Southampton University, where she studied the mechanism of action of antimicrobial peptides.
Chief Executive Officer
Jonathan Allis is the founding CEO of Blue Earth Diagnostics. Prior to this role, Jonathan was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcare’s PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc, Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany.
Jonathan is co-chair of the Society of Nuclear Medicine and Molecular Imaging Value Initiative Industry Alliance for 2018 – 2019.
Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford.
Chief Financial Officer
Jim Martin is the Chief Financial Officer at Blue Earth Diagnostics. After completing his accountancy training with Deloitte, Jim has many years’ experience in Life Sciences and Medical Diagnostics with Amersham Plc and GE Healthcare. He has held a number of senior finance, commercial and operational roles and has lived and worked internationally in the United States and Scandinavia. He is a Chartered Accountant and qualified Corporate Treasurer with a degree in Business.
Head of Imaging and Project Management
Matthew Miller is the Head of Imaging and Project Management at Blue Earth Diagnostics. Prior to this role, Matthew was a Project Leader within the Imaging R&D division at GE Healthcare and Amersham plc., overseeing PET oncology clinical trials in Europe, the United States and Asia. He has previously held positions as a Principal Medical Physicist within Imaging R&D, GE Healthcare, and as a Nuclear Medicine Physicist at the Royal London Hospital, London. Matthew has a BSc in Theoretical Physics from the University of Nottingham, an MSc in Medical Physics from the University of Surrey and a PhD in Medical Physics from the Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, in association with the University of Surrey.
Chief Operating Officer
Nick Pierce is the Chief Operating Officer at Blue Earth Diagnostics Inc., and a member of its Board of Directors. Nick began his career at KPMG, where he held various roles in both audit and transaction services and provided buy-side financial due diligence on behalf of private equity clients. Nick spent five years at Lantheus Medical Imaging, a global diagnostic imaging company, where he led the financial planning and analysis team, and reported to the CFO. Most recently, Nick was the Chief Financial Officer at Blue Earth Diagnostics in the United States. He holds a Bachelor of Science and a MBA from Babson College, with a focus on Entrepreneurship and Finance.
Chief Medical Officer
Peter Gardiner is the Chief Medical Officer at Blue Earth Diagnostics. He has more than 30 years’ experience in clinical development and medical affairs gained from roles at BG Medicine, Bristol-Myers Squibb Medical Imaging, DuPont Pharmaceuticals, Gensia and GD Searle. Most recently, he was Vice President, Medical Affairs for Blue Earth Diagnostics in the United States. Peter qualified in medicine from the University of Leeds and is Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine. He is also a scientific advisor on medical imaging to global biopharmaceutical services company PAREXEL.
Head of Quality Assurance
Richard Petherick is the Head of Quality Assurance at Blue Earth Diagnostics. He has over 20 years of experience in life sciences, the majority of which has been spent in quality-related roles. Richard has a track record of developing and improving Quality Management Systems, having held industry and consulting roles of increasing seniority. Before joining Blue Earth Richard was the Head of Quality at Britannia Pharmaceuticals. He has also held positions at GSK where he was a Director, R&D Quality and Wyeth where he worked in Global Quality and Compliance.
Richard holds an undergraduate degree from the University of Southampton.
VP Business Development and Supply Chain
Ted Broadbent is VP Business Development and Supply Chain at Blue Earth Diagnostics. Before joining Blue Earth Diagnostics, Ted managed the PET Network for GE Healthcare Life Sciences in Europe, Middle East and Africa. He has previously held positions in sales, marketing, R & D and business development at GE Healthcare, Amersham plc., Molecular Dynamics, BTTG and Bio/Gene. Ted has an undergraduate degree in Life Sciences from the University of Liverpool and a doctorate in Molecular Pathology from the University of Leeds.
Chief Commercial Officer
Terri Wilson is the Chief Commercial Officer at Blue Earth Diagnostics Inc., and a member of its Board of Directors. She has more than 20 years of experience in the PET imaging industry combined with a passion for patients and policy. Terri began her career as a nuclear medicine technologist and has held a variety of industry roles, including sales, marketing, and market access at PETNET Solutions, Siemens, Cardinal Health, and MITA (Medical Imaging & Technology Alliance). Most recently, Terri led patient access and advocacy efforts at Blue Earth Diagnostics in the United States. She holds a B.S. in Nuclear Medicine from the University of Missouri and an MBA with a focus on Pharmaceutical Marketing from Saint Joseph’s University in Philadelphia, PA. She is the immediate past chair of the MITA PET Group.
Job Title Goes Here